Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab in Multicentric Castleman's Disease
NCT01024036Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2010
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 2 trial of siltuximab in Multicentric Castleman disease (MCD), sponsored by Janssen Pharmaceutical. Started Mar 2010; status: completed.
02
Drugs
siltuximab
03
Conditions
Multicentric Castleman disease (MCD)
Beyond the preview
Go deeper on NCT01024036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01024036.